We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.13B
AUM Growth
+$109M
Cap. Flow
-$57.7M
Cap. Flow %
-5.12%
Top 10 Hldgs %
41.36%
Holding
140
New
44
Increased
20
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$38.4M
2
LLY icon
Eli Lilly
LLY
+$37.9M
3
ONCR
Oncorus, Inc.
ONCR
+$20.9M
4
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
+$19.8M
5
CCCC icon
C4 Therapeutics
CCCC
+$12.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$56.2M
2
ABBV icon
AbbVie
ABBV
+$43.2M
3
AMGN icon
Amgen
AMGN
+$28M
4
FOLD
Amicus Therapeutics
FOLD
+$20M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 67.85%
2 Technology 8.78%
3 Industrials 3.15%
4 Consumer Discretionary 1.89%
5 Communication Services 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
76
Rocket Pharmaceuticals
RCKT
$340M
$4.11M 0.37%
75,000
-153,016
-67% -$5.58M
ASND icon
77
Ascendis Pharma A/S
ASND
$16B
$3.94M 0.35%
23,599
-9,000
-28% -$1.49M
WVE icon
78
Wave Life Sciences
WVE
$1.09B
$3.27M 0.29%
414,959
-516,241
-55% -$4.33M
KDNY
79
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$3.2M 0.28%
+201,666
New +$3.04M
STTK icon
80
Shattuck Labs
STTK
$675M
$2.9M 0.26%
+55,300
New +$1.78M
ARGX icon
81
argenx
ARGX
$53.4B
$2.72M 0.24%
9,249
-1,016
-10% -$279K
ALPN
82
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.5M 0.22%
198,260
– –
SWTX
83
DELISTED
SpringWorks Therapeutics
SWTX
$2.27M 0.2%
+31,300
New +$2.01M
KA
84
DELISTED
Kineta, Inc. Common Stock
KA
$2.22M 0.2%
+18,633
New +$2.83M
DYN icon
85
Dyne Therapeutics
DYN
$4.7B
$2.1M 0.19%
100,000
+30,000
+43% +$593K
ALGS icon
86
Aligos Therapeutics
ALGS
$26.2M
$2.05M 0.18%
+2,960
New +$1.44M
LONA
87
LeonaBio Inc
LONA
$66.3M
$1.85M 0.16%
5,390
-5,810
-52% -$1.37M
CYPH
88
Cypherpunk Technologies Inc
CYPH
$62.9M
$1.8M 0.16%
80,000
– –
IACA
89
DELISTED
ION Acquisition Corp 1 Ltd.
IACA
$1.77M 0.16%
+150,000
New +$1.62M
ETNB
90
DELISTED
89bio
ETNB
$1.7M 0.15%
69,939
+11,000
+19% +$281K
BCAB icon
91
BioAtla
BCAB
$5.46M
$1.7M 0.15%
+1,000
New +$1.67M
INBX
92
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.42M 0.13%
+43,182
New +$1.15M
PVLA
93
Palvella Therapeutics
PVLA
$1.99B
$1.38M 0.12%
+6,875
New +$1.43M
BTAI icon
94
BioXcel Therapeutics
BTAI
$24.9M
$1.3M 0.12%
1,756
-15,075
-90% -$11.7M
OBIO icon
95
Orchestra BioMed
OBIO
$238M
$1.28M 0.11%
100,000
– –
SNCE
96
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$1.06M 0.09%
+5,000
New +$1.04M
KRON
97
DELISTED
Kronos Bio
KRON
$1.04M 0.09%
+35,000
New +$1.1M
VINC
98
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$972K 0.09%
+2,323
New +$732K
ACRS icon
99
Aclaris Therapeutics
ACRS
$726M
$971K 0.09%
+150,000
New +$633K
CEREW
100
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$940K 0.08%
+166,332
New +$671K
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sphera Funds Management held 140 positions worth $1.13B, up 11% from $1.02B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sphera Funds Management withdrew a net $57.7M in Q4 2020, closing 30 positions and reducing 33 holdings. Its most notable exit was Sanofi, an estimated $56.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Bristol-Myers Squibb worth $38.8M.

  • Sphera Funds Management's largest Q4 2020 buy was Bristol-Myers Squibb: 625,000 shares worth $38.8M.
  • Sphera Funds Management added most to Eli Lilly in Q4 2020, an estimated $37.9M increase.
  • Sphera Funds Management's biggest Q4 2020 reduction was AbbVie, cutting an estimated $43.2M.
  • Sphera Funds Management fully exited Sanofi in Q4 2020, selling an estimated $56.2M.
  • Sphera Funds Management's ten largest holdings make up 41% of its $1.13B portfolio in Q4 2020.
  • Sphera Funds Management opened 44 new positions and closed 30 in Q4 2020.
  • Sphera Funds Management's portfolio value rose 11% quarter-over-quarter to $1.13B.

Based on Sphera Funds Management's 13F filing for Q4 2020, filed 16 Feb 2021.